1 week Ago By ABMN Staff
Collegium Pharmaceutical, Inc. ( NASDAQ:COLL – Get Free Report ) has been given a consensus recommendation of “Moderate Buy” by the five analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company.
The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $43.60. A number of equities research analysts have recently issued reports on COLL shares.
HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.
00 price objective for the company in a research report on Friday, January 10th. Finally, Piper Sandler reduced their target price on Collegium Pharmaceutical from $37.00 to $36.
00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Read Our Latest Stock Analysis on Collegium Pharmaceutical Insider Buying and Selling Institutional Inflows and Outflows Several hedge funds and other institutional investors have recently added to or reduced their stakes in COLL. Intech Investment Management LLC bought a new stake in Collegium Pharmaceutical during the 3rd quarter valued at $374,000.
Charles Schwab Investment Management Inc. grew its stake in shares of Collegium Pharmaceutical by 4.6% in the third quarter.
Charles Schwab Investment Management Inc. now owns 381,494 shares of the specialty pharmaceutical company’s stock worth $14,741,000 after purchasing an additional 16,655 shares during the last quarter. FMR LLC increased its holdings in Collegium Pharmaceutical by 1,532.
2% during the 3rd quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock valued at $1,459,000 after purchasing an additional 35,439 shares during the period. Verition Fund Management LLC raised its position in Collegium Pharmaceutical by 35.
1% during the 3rd quarter. Verition Fund Management LLC now owns 14,042 shares of the specialty pharmaceutical company’s stock valued at $543,000 after purchasing an additional 3,652 shares during the last quarter. Finally, ClearAlpha Technologies LP bought a new position in Collegium Pharmaceutical during the 3rd quarter valued at approximately $266,000.
Collegium Pharmaceutical Trading Up 2.1 % NASDAQ COLL opened at $30.00 on Friday.
Collegium Pharmaceutical has a 12 month low of $27.28 and a 12 month high of $42.29.
The stock has a 50-day simple moving average of $30.16 and a 200 day simple moving average of $32.28.
The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.
43. The company has a market capitalization of $944.58 million, a PE ratio of 12.
93 and a beta of 0.99. Collegium Pharmaceutical ( NASDAQ:COLL – Get Free Report ) last posted its earnings results on Thursday, February 27th.
The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.
09. The firm had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.
68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.
78%. Research analysts forecast that Collegium Pharmaceutical will post 5.62 EPS for the current year.
About Collegium Pharmaceutical ( Get Free Report Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Read More Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.
com's FREE daily email newsletter ..
_0.jpg?itok=Jn8RJQZW)
